PDF(Pubmed)
Abstract：
UNASSIGNED: Bone metastases in thyroid cancer impair the patient\'s quality of life and prognosis. Interestingly, wide margins resection as the surgical treatment of bone metastases might improve the overall survival (OS). Nonetheless, data are lacking regarding the potential benefits of this strategy.
UNASSIGNED: In order to assess the OS of patients with thyroid cancer after a bone metastases carcinologic resection, a retrospective multicentric study was performed, evaluating the 1, 5, 10 and 15 years-OS along with the potential prognosis associated factors.
UNASSIGNED: 40 patients have been included in this multicentric study, with a mean follow-up after surgery of 46.6 ± 58 months. We observed 25 (62.5%) unimestastatic patients and 15 multimetastatic patients (37.5%). The median overall survival after resection was 48 ± 57.3 months. OS at 1, 5, 10, and 15 years was respectively 76.2%, 63.6%, 63.6%, and 31.8%. Survival for patients with a single bone metastasis at 15 year was 82.3%, compared with 0.0% (Log Rank, p = 0.022) for multi-metastatic bone patients.
UNASSIGNED: This study advocates for an increased long term 10-year OS in patients with thyroid cancer, after resection of a single bone metastasis, suggesting the benefits of this strategy in this population.
UNASSIGNED: In order to assess the OS of patients with thyroid cancer after a bone metastases carcinologic resection, a retrospective multicentric study was performed, evaluating the 1, 5, 10 and 15 years-OS along with the potential prognosis associated factors.
UNASSIGNED: 40 patients have been included in this multicentric study, with a mean follow-up after surgery of 46.6 ± 58 months. We observed 25 (62.5%) unimestastatic patients and 15 multimetastatic patients (37.5%). The median overall survival after resection was 48 ± 57.3 months. OS at 1, 5, 10, and 15 years was respectively 76.2%, 63.6%, 63.6%, and 31.8%. Survival for patients with a single bone metastasis at 15 year was 82.3%, compared with 0.0% (Log Rank, p = 0.022) for multi-metastatic bone patients.
UNASSIGNED: This study advocates for an increased long term 10-year OS in patients with thyroid cancer, after resection of a single bone metastasis, suggesting the benefits of this strategy in this population.
摘要：
■甲状腺癌骨转移会损害患者的生活质量和预后。有趣的是,广泛的切缘切除作为骨转移的手术治疗可能会提高总生存率（OS）。尽管如此，缺乏有关此策略潜在好处的数据。
■为了评估骨转移癌切除术后甲状腺癌患者的OS，进行了一项回顾性多中心研究，评估1、5、10和15年OS以及潜在的预后相关因素。
■这项多中心研究已包括40名患者，术后平均随访46.6±58个月。我们观察到25例（62.5％）未住院患者和15例多住院患者（37.5％）。切除后的中位总生存期为48±57.3个月。1年、5年、10年和15年的OS分别为76.2%，63.6%,63.6%,和31.8%。单个骨转移患者15年生存率为82.3%,与0.0%(对数排名，p=0.022）用于多转移性骨患者。
■这项研究主张增加甲状腺癌患者的长期10年OS，切除单个骨转移后，表明这种策略在这个人群中的好处。
■为了评估骨转移癌切除术后甲状腺癌患者的OS，进行了一项回顾性多中心研究，评估1、5、10和15年OS以及潜在的预后相关因素。
■这项多中心研究已包括40名患者，术后平均随访46.6±58个月。我们观察到25例（62.5％）未住院患者和15例多住院患者（37.5％）。切除后的中位总生存期为48±57.3个月。1年、5年、10年和15年的OS分别为76.2%，63.6%,63.6%,和31.8%。单个骨转移患者15年生存率为82.3%,与0.0%(对数排名，p=0.022）用于多转移性骨患者。
■这项研究主张增加甲状腺癌患者的长期10年OS，切除单个骨转移后，表明这种策略在这个人群中的好处。
